Universitätsklinikum Essen

Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide: an international collaborative (2021) Kayser S, Schlenk RF, Lebon D, Carre M, Goetze KS, Stoelzel F, Berceanu A, et al. Journal article Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program (2021) Müller V, Banys-Paluchowski M, Friedl TW, Fasching P, Schneeweiss A, Hartkopf A, Wallwiener D, et al. Journal article Rationale and design of the 2 by 2 factorial design GnG-trial: a randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AML (2021) Jaramillo S, Krisam J, Le Cornet L, Kratzmann M, Baumann L, Sauer T, Crysandt M, et al. Journal article Multimodal analysis of cell-free DNA whole-genome sequencing for pediatric cancers with low mutational burden (2021) Peneder P, Stütz AM, Surdez D, Krumbholz M, Semper S, Chicard M, Sheffield NC, et al. Journal article Detection of gene fusions using targeted next-generation sequencing: a comparative evaluation (2021) Heydt C, Wölwer CB, Velazquez Camacho O, Wagener-Ryczek S, Pappesch R, Siemanowski J, Rehker J, et al. Journal article Interleukin-3 is a predictive marker for severity and outcome during SARS-CoV-2 infections (2021) Bénard A, Jacobsen A, Brunner M, Krautz C, Klösch B, Swierzy I, Naschberger E, et al. Journal article Characteristics and Outcome of Patients with Acute Myeloid Leukemia and Trisomy 4 (2021) Kayser S, Martinez-Cuadron D, Hanoun M, Stoelzel F, Gil C, Reinhardt HC, Aguiar E, et al. Conference contribution Real-World Experience of CPX-351 As First-Line Treatment in 188 Patients with Acute Myeloid Leukemia (2021) Rautenberg C, Stoelzel F, Roellig C, Stelljes M, Gaidzik V, Lauseker M, Kriege O, et al. Conference contribution Late Non-Relapse Mortality (NRM) after Standard-of-Care (SOC) CAR-T Cell Therapy for Large B-Cell Lymphoma (LBCL): Frequency, Causes, and Risk Factors.a GLA/DRST Real World Analysis (2021) Dreger P, Schubert ML, Holtick U, Subklewe M, Von Bastian T, Ayuk FA, Wagner EM, et al. Conference contribution Impact of Body Mass Index on Patient Outcome in Acute Myeloid Leukemia Patients Receiving Intensive Induction Therapy: A Real-World Registry Experience (2021) Enssle JC, Wolf S, Scheich S, Weber S, Kramer M, Ruhnke L, Schliemann C, et al. Conference contribution